LONDON (ShareCast) - (Sharecast News) - Oxford BioDynamics announced on Wednesday that it has signed a distribution agreement with Regina Maria, Romania's largest private healthcare provider, to offer its EpiSwitch PSE and CiRT blood tests to physicians and patients across the country.
The AIM-traded firm said the tests, part of its precision diagnostics portfolio, would be integrated into Regina Maria's oncology services.

Regina Maria operates eight hospitals, 60 polyclinics, 36 laboratories and over 100 blood collection points, serving five million patients.

Under the agreement, blood samples for the EpiSwitch tests would be processed at OBD's UKAS-accredited clinical laboratory in Oxford.

The company described the EpiSwitch PSE test as a highly accurate prostate cancer screening tool designed to improve upon traditional PSA testing, with a reported accuracy of 94%.

It said it aims to reduce unnecessary MRI scans and biopsies for men without prostate cancer.

The EpiSwitch CiRT test meanwhile helps identify patients likely to respond to immune checkpoint inhibitors, assisting oncologists in treatment planning.

"OBD welcomes Regina Maria as our partner, as we continue to work diligently to broaden availability of our diagnostic tests through partnerships," said executive chairman Iain Ross.

"Through this collaboration, we aim to ensure that patients in Romania - the first in the EU to adopt EpiSwitch clinical tests into private healthcare - have convenient, widespread access to EpiSwitch PSE as a highly accurate test for prostate cancer risk, and EpiSwitch CiRT for those considering or on cancer immunotherapy."

At 1114 GMT, shares in Oxford BioDynamics were up 2.5% at 0.51p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE